#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

Continue reading